CAR-T CD30 for Hodgkin’s Lymphoma用于治疗晚期弥漫大B细胞淋巴瘤的CAR-T CD30

Home / CAR-T CD30 for Hodgkin’s Lymphoma用于治疗晚期弥漫大B细胞淋巴瘤的CAR-T CD30


CAR-T CD30 for progressive relapsed/refractory Hodgkin’s lymphoma

Chimeric Antigen Receptor T cell (CAR-T) therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors. TRIAL DATA Phase I Clinical Trial – VIEW PRESS HERE May 22, 2015

Name of StudyCD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
PhaseClinical Trial Phase I
ClinicalTrials.gov IdentifierNCT02259556 - view study online here
Study TypeInterventional
Study DesignEndpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Principal InvestigatorWei Dong Han, MD, PhD
Hospital(s)Chinese PLA General Hospital (PLAGH)

用于治疗晚期弥漫大B细胞淋巴瘤的CAR-T CD30

嵌合抗原受体T细胞(CAR-T)疗法通过改造癌症患者自身的免疫细胞,识别并攻击肿瘤。

研究名称 CD30-引导嵌合抗原受体T(CART30)疗法用于治疗复发性和难治性CD30阳性 淋巴癌
阶段临床试验阶段I
ClinicalTrial.gov标识符NCT02259556 - 点击此处在线查看研究
研究类型介入性
研究设计 介入模型:单组分配
掩蔽:非盲
主要目标:治疗
主要研究者Wei Dong Han, 博士
医院 中国人民解放军总医院(PLAGH)